Multicenter Uveitis Steroid Treatment (MUST)
Investigators are comparing two currently available treatments for uveitis. Systemic treatment utilizing medications taken orally, by injection, or by intravenous infusion is being compared to treatment with an intraocular implant containing corticosteroid.
Investigators: Gary N. Holland, MD, Jean-Pierre Hubschman, MD, and Ralph D. Levinson, MD
Corticosteroids for Uveitic Macular Edema
The purpose of this research study is to compare three treatments for macular edema in patients who have the eye condition uveitis (inflammation inside the eye). Macular edema is swelling of the retina at the back of the eye. It can cause vision loss. The standard treatments are to inject corticosteroid drugs next to the eye or directly into the eye.
Investigators: Gary N. Holland, MD, and Colin McCannel, MD
Macular Edema Ranibizumab v. Intravitreal anti-inflammatory Therapy Trial
The MERIT Trial was designed to find out which intravitreal therapy offers the best balance of effectiveness and tolerability in treating persistent uveitic macular edema in eyes with controlled uveitis but persistent macular edema, specifically by comparing the relative efficacy and safety of intravitreal ranibizumab (Lucentis®) and intravitreal methotrexate to intravitreal dexamethasone implant (Ozurdex®) for the treatment of persistent uveitic macular edema.
Investigators: Gary N. Holland, MD
